Medicine for treating cardiovascular diseases and preparation method thereof

By developing ligustrazine derivatives, the adverse reactions and drug resistance problems of existing cardiovascular disease treatment drugs have been solved, and significant anti-inflammatory, lipid-lowering and cardiovascular protection effects have been achieved, providing a potentially efficient cardiovascular disease treatment drug .

CN118908950AActive Publication Date: 2024-11-08CIXI PEOPLES HOSPITAL MEDICAL HEALTH GRP (CIXI PEOPLES HOSPITAL) +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410976146.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

There are adverse reactions and drug resistance problems in existing cardiovascular disease treatment drugs. Ligustrazine cannot effectively play a cardiovascular protection role at low doses, and it is necessary to develop drugs with excellent cardiovascular protection effects.

Method used

A ligustrazine derivative was developed to form drugs with significant anti-inflammatory, lipid-lowering and cardiovascular protection effects through specific compound structures and preparation methods for the treatment of cardiovascular diseases.

Benefits of technology

This ligustrazine derivative is significantly better than ligustrazine in anti-inflammatory, lipid-lowering and cardiovascular protection effects. The simple and easy preparation method is suitable for large-scale production and has potential prospects for the treatment of cardiovascular diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908950A_ABST
    Figure CN118908950A_ABST
Patent Text Reader

Abstract

The invention relates to a medicine for treating cardiovascular diseases and a preparation method thereof. The medicine is a ligustrazine derivative shown in the formula I. The medicine has the anti-inflammatory, lipid-lowering and cardiovascular protection effects obviously better than that of ligustrazine, the preparation method is simple and easy to implement, large-scale production can be achieved, and the medicine is a potential and promising cardiovascular disease treatment medicine. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical chemistry, and in particular to a drug for treating cardiovascular diseases and a preparation method thereof. Background Art

[0002] Cardiovascular disease (CVD) seriously endangers human health. At present, China has a large population of CVD patients, and its mortality rate ranks first. With the acceleration of population aging and unhealthy behaviors in residents' lives, the prevalence of CVD continues to rise.

[0003] At present, statins, aspirin, beta-blockers, calcium channel blockers, angiotensin II receptor antagonists, angiotensin converting enzyme inhibitors and nitrates are commonly used in clinical practice to prevent and treat CVD. However, with its widespread use in clinical practice, adverse reactions have gradually emerged. Simvastatin and atorvastatin in statins have a higher risk of rhabdomyolysis. Patients treated with angiotensin converting enzyme inhibitors have a higher incidence of bronchospasm and cough. In addition, beta-blockers inhibit sympathetic nerve excitation and mask the symptoms of hypoglycemia. They are contraindicated in patients with acute left heart failure, bronchial asthma, asymptomatic hypoglycemia and atrioventricular block of degree II or above.

[0004] Traditional Chinese medicine has shown unique advantages in the prevention and treatment of CVD. It complements Western medicine in protecting people's health, can significantly improve patients' symptoms, reduce the occurrence of adverse reactions, and is widely used in clinical practice. Small molecule monomers derived from traditional Chinese medicine have low toxicity, are not easy to develop drug resistance, and have a high patient acceptance rate. Finding compounds with cardiovascular protective effects from traditional Chinese medicine is a hot topic in current research. It has been found that a large number of compounds in flavonoids, flavonols, isoflavones, chalcones, cyclopentanes, triterpenoid saponins, and alkaloids have cardiovascular protective effects. Among them, ligustrazine is a biologically active traditional Chinese medicine monomer component extracted from the rhizome of Ligusticum chuanxiong, a plant of the genus Ligusticum in the Apiaceae family. In addition to the traditional effects of promoting blood circulation and removing blood stasis, inhibiting platelet aggregation, dilating blood vessels, improving blood circulation, and relieving pain, as research continues to deepen, it has been found that ligustrazine also has the effects of preventing and treating cardiovascular and cerebrovascular diseases, repairing ischemia-reperfusion injury in multiple organs such as the heart, brain tissue, and kidneys, protecting vascular endothelium, inhibiting tumors, airway remodeling in asthma patients, inhibiting calcium overload, and immunomodulating, and can be used as a cardiovascular protective drug. However, the active monomers of traditional Chinese medicine often have the problem of insufficient efficacy, and ligustrazine is the same. It cannot play a good cardiovascular protective role under low-dose conditions, so it is necessary to develop cardiovascular therapeutic drugs with more prominent efficacy. Summary of the invention

[0005] The purpose of the present invention is to provide a ligustrazine derivative which has excellent cardiovascular protective effect and can be used as a drug for treating various cardiovascular diseases.

[0006] The ligustrazine derivatives of the present invention are compounds represented by formula I or pharmaceutically acceptable salts, solvates, hydrates, prodrugs, and tautomers thereof:

[0007]

[0008] wherein R1-R3 are the same or different, and are independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, and R1-R3 are not all hydrogen;

[0009] L is selected from C1-C6 alkylene;

[0010] R4 and R5 are the same or different and are independently selected from hydrogen, C1-C6 alkyl, and halogenated C1-C6 alkyl;

[0011] X is selected from O or S.

[0012] In another aspect, the present invention also provides a method for preparing the compound of formula I.

[0013] In another aspect, the present invention also provides a use of the compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof in the preparation of a drug for treating cardiovascular diseases.

[0014] In another aspect, the present invention also provides a method for treating cardiovascular diseases.

[0015] In another aspect, the present invention also provides a pharmaceutical composition comprising the compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof. DETAILED DESCRIPTION

[0016] It should be understood that the terms or words used in the specification and claims should not be understood as having the meaning defined in the dictionary, but should be understood as having the meaning consistent with their meaning in the context of the present invention based on the following principle: the concept of the term can be appropriately defined by the inventor for the best explanation of the present invention.

[0017] In the present invention, the term "halogen" means fluorine, chlorine, bromine or iodine.

[0018] In the present invention, the term "alkyl" whether used alone or as part of a substituent includes saturated straight or branched hydrocarbon groups, preferably containing 1 to 10 carbon atoms, more preferably containing 1 to 6 carbon atoms, and most preferably containing 1 to 4 carbon atoms. Examples of the alkyl include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl, pentyl, hexyl, but are not limited thereto.

[0019] In the present invention, the term "haloalkyl" refers to an alkyl group substituted with halogen at any position. Thus, "haloalkyl" includes the above definitions of halogen and alkyl.

[0020] In the present invention, the term "pharmaceutically acceptable salt" refers to an addition salt formed by an active compound and a pharmaceutically acceptable acid, which is relatively non-toxic to the patient and has harmless activity, and its side effects do not reduce the beneficial effects of the active compound. The acid includes: inorganic acids such as hydrochloric acid, bromic acid, nitric acid, sulfuric acid, perchloric acid and phosphoric acid; or organic acids such as citric acid, acetic acid, lactic acid, maleic acid, fumaric acid, methanesulfonic acid, succinic acid, tartaric acid, galacturonic acid, pamoic acid, glutamic acid, aspartic acid, oxalic acid, (D) or (L) malic acid, methanesulfonic acid, ethanesulfonic acid, 4-toluenesulfonic acid, salicylic acid, citric acid, benzoic acid and malonic acid.

[0021] In the present invention, the term "solvate" refers to a compound form that forms a complex in a solid or liquid state by coordination with a solvent molecule. When the solvent molecule is a water molecule, the solvate is a hydrate.

[0022] In the present invention, the term "prodrug" refers to a compound that is converted into an active compound as a result of a reaction in vivo with an enzyme, gastric acid, etc. As prodrugs, many types of prodrugs are known, and suitable prodrugs can be selected from known literature and synthesized by known methods.

[0023] In the present invention, "tautomers" refer to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible, a chemical equilibrium of tautomers can be achieved. For example, proton tautomers are also called prototropic tautomers. They include interconversions through proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include interconversions through the reorganization of some bonding electrons.

[0024] The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof:

[0025]

[0026] wherein R1-R3 are the same or different, and are independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, and R1-R3 are not all hydrogen;

[0027] L is selected from C1-C6 alkylene;

[0028] R4 and R5 are the same or different and are independently selected from hydrogen, C1-C6 alkyl, and halogenated C1-C6 alkyl;

[0029] X is selected from O or S.

[0030] In one embodiment, R1-R3 are the same or different and are independently selected from hydrogen, methyl, ethyl, hydroxymethyl, trifluoromethyl.

[0031] In one embodiment, R1-R3 are all selected from methyl.

[0032] In one embodiment, R1, R2 are selected from hydrogen, and R3 is selected from methyl or trifluoromethyl.

[0033] In one embodiment, L is selected from -(CH2) m -, m is 1, 2, 3, 4, 5 or 6.

[0034] In one embodiment, L is selected from -CH2-, -CH2CH2-.

[0035] In one embodiment, R4 and R5 are the same or different and are independently selected from hydrogen, methyl and ethyl.

[0036] In a preferred embodiment, the compound is selected from:

[0037]

[0038] In another aspect, the present invention also provides a method for preparing the compound of formula I, the method comprising:

[0039]

[0040] wherein Xa represents a halogen;

[0041] Step 1: reacting a compound of formula a with hydrazine hydrate to produce an intermediate of formula b;

[0042] Step 2: React the intermediate of formula b with an aldehyde of formula c to produce a compound of formula I.

[0043] Preferably, Xa represents chlorine or bromine.

[0044] Preferably, step 1 is carried out in the presence of a base selected from sodium carbonate, potassium carbonate or cesium carbonate.

[0045] In another aspect, the present invention also provides a use of the compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof in the preparation of a drug for treating cardiovascular diseases.

[0046] In another aspect, the present invention also provides a method for treating cardiovascular diseases, comprising administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof to a patient in need thereof.

[0047] In one embodiment, the cardiovascular disease includes coronary heart disease, angina pectoris, atherosclerosis, hyperlipidemia, and myocardial infarction.

[0048] In one embodiment, the compound of formula I or its pharmaceutically acceptable salt, solvate, hydrate, prodrug, tautomer of the present invention can also be used to prepare cardiovascular protective drugs. The cardiovascular protective drugs can reduce cardiovascular damage caused by cardiovascular diseases.

[0049] In another aspect, the present invention also provides a pharmaceutical composition comprising the compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof.

[0050] In one embodiment, the pharmaceutical composition optionally further comprises one or more pharmaceutically acceptable carriers or excipients.

[0051] Representative carriers include, for example, water, buffers, ethanol, mineral oils, vegetable oils, dimethyl sulfoxide, carbohydrates, mannitol and proteins. Additional optional components include adjuvants, diluents, polypeptides or amino acids such as sugar gums, antioxidants, chelating agents such as EDTA or glutathione and / or preservatives. Preferred pharmaceutical compositions are formulated into oral dosage forms for humans or animals.

[0052] Pharmaceutically acceptable carriers must have sufficiently high purity and sufficiently low toxicity to make them suitable for administration to the treated animal. The carrier may be inert or it may have pharmaceutical benefits. The amount of carrier used with the compound is sufficient to provide a practical amount of the administered substance per unit dose of the compound. Representative pharmaceutically acceptable carriers or components thereof are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and methylcellulose; tragacanth powder; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; synthetic oils; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; polyols such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; phosphate buffer; emulsifiers such as Tweens; wetting agents such as sodium lauryl sulfate; colorants; flavorings; tableting; stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline; and phosphate buffer.

[0053] To prepare a pharmaceutical composition, an effective concentration of a compound of formula I of the present invention or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, tautomer thereof is mixed with one or more suitable pharmaceutically acceptable carriers or excipients. In the case of insufficient solubility of the compound, a method for solubilizing the compound can be used. Such methods are well known to those skilled in the art, and include but are not limited to using a cosolvent such as dimethyl sulfoxide, using a surfactant such as tween, or being dissolved in an aqueous sodium bicarbonate solution. After mixing or adding the compound, the mixture formed can be a solution, a suspension, an emulsion or the like. The form of the mixture formed depends on a number of factors, including the intended mode of administration and the solubility of the compound in the selected carrier.

[0054] The pharmaceutical composition can be formulated to be administered by any route, including oral, topical, parenteral, by inhalation or spray, sublingual, transdermal, by oral administration, rectal administration, as eye drops or by other means, and can be made into unit dose formulations. Suitable for oral dosage formulations include, for example, tablets, tablets, lozenges, transparent solutions, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, tinctures, syrups or elixirs. Compounds for oral administration may also contain one or more optional agents such as sweeteners, aromatics, coloring agents and preservatives to provide pharmaceutically desirable and delicious preparations. Such configurations may also contain analgesics. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water.

[0055] Liquid formulations for oral administration Compound provided by the invention can be included in oral liquid preparations, for example, in aqueous or oily suspensions, solutions, emulsions, syrups or elixirs. In addition, the preparaton containing these compounds can exist as dry products, for use before use with water or other suitable vehicle combinations. This type of liquid preparation can also contain one or more conventional additives, such as suspending agents, emulsifying agents and / or non-aqueous vehicles such as edible oils and preservatives.

[0056] Dispersible powders Dispersible powders or granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those mentioned above.

[0057] Tablets and Capsules Tablets typically include conventional pharmaceutically compatible inert diluents such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid; and / or lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve the fluidity of the powder mixture. Colorants and dyes can be added to improve the appearance. Sweeteners and flavoring agents are effective adjuvants for chewable tablets. Capsules typically include one or more of the above solid diluents. The choice of carrier components usually depends on secondary considerations such as taste, cost and shelf life.

[0058] Injection or parenteral formulation pharmaceutical composition can be in the form of sterile injection water or oil suspension. Such suspension can be prepared according to known technology using the above-mentioned dispersion or wetting agent and suspending agent. The sterile injection preparation can also be a sterile injection solution or suspension in a non-toxic parent acceptable diluent or solvent. Among acceptable vehicles and solvents, water, Ringer's solution and isotonic sodium chloride solution can be adopted. In addition, non-toxic, non-volatile oil is conventionally used as solvent or suspension medium.

[0059] The pharmaceutical composition can also be topically administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.Liposomes can be formed from a variety of phospholipids such as cholesterol, stearylamine or phosphatidylcholine.

[0060] Compositions for inhalation are typically provided in the form of solutions, suspensions or emulsions which can be administered as dry powders, or in the form of aerosols using conventional propellants.

[0061] The compound of formula I of the present invention or its pharmaceutically acceptable salt, solvate, hydrate, prodrug, tautomer is usually present in a therapeutically effective amount in a pharmaceutical composition. It is preferred to provide a composition with a dosage level ranging from about 0.1 mg to about 140 mg per kilogram of body weight per day (about 0.5 mg to about 7 g per patient per day), and a dosage ranging from 0.1 mg to 50 mg, 30 mg or 10 mg is particularly preferred. However, it should be understood that the optimal dose for any particular patient varies according to multiple factors, including the activity of the specific drug used; the patient's age, weight, overall health, sex and diet; the time and route of administration; excretion rate; any simultaneous treatment such as drug combination; and the type and severity of the specific disease to be treated. The dosage form usually contains about 10 μg to about 500 mg of the compound of formula I of the present invention or its pharmaceutically acceptable salt, solvate, hydrate, prodrug, tautomer. The optimal dose can be established using conventional tests and procedures known in the art.

[0062] The compounds of the present invention may be combined or used in combination with other agents that can be used to treat, prevent, inhibit or improve diseases or conditions for which the compounds of the present invention are useful. To this end, the present invention provides a pharmaceutical combination comprising the compounds of the present invention and other agents that can be used to treat, prevent, inhibit or improve diseases or conditions for which the compounds of the present invention are useful.

[0063] Beneficial effects: The present invention provides a drug for treating cardiovascular diseases and a preparation method thereof. The drug for treating cardiovascular diseases of the present invention is a ligustrazine derivative, which is derived from ligustrazine as a lead compound, and the compound has significantly better anti-inflammatory, lipid-lowering and cardiovascular protection effects than ligustrazine. The preparation method is simple and easy, and can be mass-produced. Therefore, the compound is a potential and promising drug for treating cardiovascular diseases. Specific embodiments

[0065] The present invention is described in more detail hereinafter to facilitate understanding of the present invention.

[0066] It should be understood that the terms or words used in the specification and claims should not be understood to have the meaning defined in the dictionary, but should be understood to have the meaning consistent with its meaning in the context of the present invention on the basis of the following principles: the concept of the term can be appropriately defined by the inventor for the best description of the present invention. Preferred methods and materials are described below, but methods and materials similar or equivalent to the methods and materials described herein can also be used in the practice or testing of the present invention. The materials, methods and examples disclosed herein are only illustrative and are not intended to be limiting.

[0067] Example 1: Preparation of the compound of formula 1

[0068]

[0069] Step 1. Add the compound of formula a-1 (3.4 g, 20 mmol) to hydrazine hydrate (80%, 10 g) in batches at room temperature with stirring. After the addition is complete, add potassium carbonate (5.5 g, 40 mmol), continue stirring for 15 min, then heat to 40°C, and monitor the reaction by TLC. The reaction is complete after 5 hours. After cooling, add 100 ml of dichloromethane and 50 ml of water, mix thoroughly, and then stand to separate. The aqueous phase is extracted with dichloromethane (80 ml × 2), and all organic phases are combined, washed with saturated sodium chloride aqueous solution and water, respectively, dried over anhydrous sodium sulfate, filtered, and the solvent is evaporated under reduced pressure to obtain a solid residue, which is the intermediate of formula b-1; it is directly used in the next reaction without purification.

[0070] Step 2. The product of the previous step, the aldehyde of formula c-1 (1.94 g, 20 mmol), was dissolved in 50 ml of ethanol, stirred at room temperature for 2 h, the precipitate was collected by filtration, and recrystallized from acetonitrile to obtain compound 1, 4.12 g, purity 99.4%, yield 84.1%.

[0071] MS m / z:246.2[M+H] +

[0072] Elemental analysis: C 12 H 15 Theoretical value of N5O: C, 58.76; H, 6.16; N, 28.55; O, 6.52; Actual value: C, 58.78; H, 6.15; N, 28.53; O, 6.50.

[0073] 1 H NMR (400MHz, DMSO-d6) δ9.33(t,J=7.0Hz,1H),8.46(s,1H),8.12(s,1H),7.91(s,1H),4.47(d,J=7.1Hz,2H),2.34(s,3H),2.25(s,3H),2.22(s,3H).

[0074] Example 2: Preparation of the compound of formula 2

[0075]

[0076] Step 1. Add the compound of formula a-1 (1.7 g, 10 mmol) to hydrazine hydrate (80%, 5 g) in batches at room temperature with stirring. After the addition is complete, add potassium carbonate (2.7 g, 20 mmol), continue stirring for 15 min, then heat to 40°C and monitor the reaction by TLC. The reaction is complete after 5 hours. After cooling, add 60 ml of dichloromethane and 30 ml of water, mix thoroughly and stand to separate. The aqueous phase is extracted with dichloromethane (30 ml × 2). All organic phases are combined, washed with saturated sodium chloride aqueous solution and water respectively, dried over anhydrous sodium sulfate, filtered, and the solvent is evaporated under reduced pressure to obtain a solid residue, which is the intermediate of formula b-1; it is directly used in the next reaction without purification.

[0077] Step 2. The product of the previous step, aldehyde of formula c-2 (1.13 g, 10 mmol), was dissolved in 30 ml of ethanol, stirred at room temperature for 2 h, the precipitate was collected by filtration, and recrystallized from acetonitrile to obtain compound 2, 2.27 g, purity 99.5%, yield 87.0%.

[0078] MS m / z:262.2[M+H] +

[0079] Elemental analysis: C 12 H 15 Theoretical value of N5S: C, 55.15; H, 5.79; N, 26.80; S, 12.27; actual value: C, 55.12; H, 5.77; N, 26.83; S, 12.26.

[0080] 1 H NMR (400MHz, DMSO-d6) δ9.16(t,J=7.0Hz,1H),8.79(s,1H),8.05(s,1H),7.55(s,1H),4.46(d,J=7.1Hz,2H),2.34(s,3H),2.25(s,3H),2.22(s,3H).

[0081] Example 3: Preparation of the compound of formula 3

[0082]

[0083] Step 1. Add the compound of formula a-3 (3.7 g, 20 mmol) to hydrazine hydrate (80%, 10 g) in batches at room temperature with stirring. After the addition is complete, add potassium carbonate (5.5 g, 40 mmol), continue stirring for 15 min, then heat to 40°C, and monitor the reaction by TLC. The reaction is complete after 4 hours. After cooling, add 100 ml of dichloromethane and 50 ml of water, mix thoroughly, and then stand to separate. The aqueous phase is extracted with dichloromethane (80 ml × 2), and all organic phases are combined, washed with saturated sodium chloride aqueous solution and water, respectively, dried over anhydrous sodium sulfate, filtered, and the solvent is evaporated under reduced pressure to obtain a solid residue, which is the intermediate of formula b-3; it is directly used in the next reaction without purification.

[0084] Step 2. The product of the previous step, the aldehyde of formula c-1 (1.94 g, 20 mmol), was dissolved in 70 ml of ethanol, stirred at room temperature for 2 h, the precipitate was collected by filtration, and recrystallized from tetrahydrofuran to obtain compound 3, 3.95 g, purity 99.2%, yield 91.0%.

[0085] MS m / z:218.2[M+H] +

[0086] Elemental analysis: C 10 H 11 Theoretical value of N5O: C, 55.29; H, 5.10; N, 32.24; O, 7.36; Actual value: C, 55.26; H, 5.12; N, 32.21; O, 7.38.

[0087] 1 H NMR (400MHz, DMSO-d6) δ9.41 (t, J = 7.0 Hz, 1H), 8.46 (s, 1H), 8.31-8.23 (m, 2H), 8.12 (s, 1H), 7.91 (s, 1H), 4.60 (d, J = 7.1Hz, 2H), 2.37 (s, 3H).

[0088] Example 4: Preparation of the compound of formula 3

[0089]

[0090] Step 1. Add the compound of formula a-4 (2.4 g, 10 mmol) to hydrazine hydrate (80%, 5 g) in batches at room temperature with stirring. After the addition is complete, add potassium carbonate (2.7 g, 20 mmol), continue stirring for 15 min, then heat to 40°C, and monitor the reaction by TLC. The reaction is complete after 4 hours. After cooling, add 60 ml of ethyl acetate and 30 ml of water, mix thoroughly, and then stand to separate. The aqueous phase is extracted with ethyl acetate (30 ml × 2), and all organic phases are combined, washed with saturated sodium chloride aqueous solution and water, respectively, dried over anhydrous sodium sulfate, filtered, and the solvent is evaporated under reduced pressure to obtain a solid residue, which is the intermediate of formula b-4; it is directly used in the next reaction without purification.

[0091] Step 2. The product of the previous step, aldehyde of formula c-2 (1.13 g, 10 mmol), was dissolved in 30 ml of methanol and stirred at room temperature for 2 h. The precipitate was collected by filtration and recrystallized from tetrahydrofuran to obtain compound 4, 2.57 g, purity 99.4%, yield 89.2%.

[0092] MS m / z:288.1[M+H] +

[0093] Elemental analysis: C 10 Theoretical values ​​of H8F3N5S are C, 41.81; H, 2.81; F, 19.84; N, 24.38; S, 11.16; actual values ​​are: C, 41.83; H, 2.80; F, 19.86; N, 24.39; S, 11.13.

[0094] 1 H NMR (400MHz, DMSO-d6) δ9.22 (t, J = 6.2 Hz, 1H), 8.79 (s, 1H), 8.33 (m, 2H), 8.05 (s, 1H), 7.55 (s, 1H), 4.76 (d, J = 6.2Hz, 2H).

[0095] Example 5: Protective effect of the compounds of the present invention on rats with coronary heart disease

[0096] Fifty SD rats (6 weeks old, weight 190±20g, purchased from Shanghai Slake Experimental Animal Co., Ltd.) were fed adaptively at 22±2℃ and 50±10% humidity for 1 week before the experiment. They were randomly divided into 5 groups, including normal group, model group, ligustrazine group, compound 1 group, and compound 4 group, with 10 rats in each group. Each rat was weighed and recorded as the initial weight. The rats in the normal group were given a basic feed and intraperitoneally injected with 0.9% sodium chloride solution at 2ml / kg for 3 times for 3 consecutive days; the rats in the other groups were fed with a compound high-fat feed and intraperitoneally injected with vitamin D3 at 2ml / kg for 3 times for 3 consecutive days. The formula of the compound high-fat feed: 3.5% cholesterol, 10% lard, 10% egg yolk powder, 0.2% sodium cholate, 0.2% propylthiouracil, 7% sucrose, and 69.1% ordinary feed. After continuous feeding for 12 weeks, rats in each group were anesthetized by intraperitoneal injection of 10% chloral hydrate, and the electrocardiogram of lead II of the rats was recorded to observe ST segment changes. The ST segment elevation of the rat electrocardiogram ≥ 0.1mV was used as a sign of successful modeling. After successful modeling, the ligustrazine group, compound 1 group, and compound 4 group were intraperitoneally injected with 20mg / ml of the drug at 40mg / kg, and the normal group and model group were intraperitoneally injected with an equal volume of 0.9% sodium chloride solution. During the administration period, rats in each group were free to eat. After continuous administration for 4 weeks, the rats in each group were weighed again, recorded as the final weight, and the weight gain of rats in each group was calculated (final weight - initial weight). Subsequent experiments were carried out 24h after the last administration.

[0097] 1. Determination of TNF-α, IL-6 and IL-1β levels

[0098] 24 hours after the last administration of the rats, blood was collected from the retro-orbital venous plexus into a centrifuge tube rinsed with heparin, left to stand at room temperature for 5 minutes, and then placed in a centrifuge at 4°C, 3500 r / min for 10 minutes. The supernatant was taken and the levels of TNF-α, IL-6 and IL-1β in rat plasma were detected according to the instructions of the ELISA kit.

[0099] 2. Determination of total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels

[0100] After rats were anesthetized by intraperitoneal injection of sodium pentobarbital, blood was collected from the abdominal aorta into a centrifuge tube, left to stand at 4°C for 4 hours, and then placed in a centrifuge at 4°C, 3500r / min for 10 minutes. The supernatant was taken and the serum total cholesterol, triglyceride, HDL-C, and LDL-C levels were measured using an automatic biochemical analyzer to calculate the atherosclerosis index (AI). AI = (total cholesterol - HDL-C) / HDL-C.

[0101] 3. Endothelial Function Assay

[0102] Five rats were anesthetized in each group. The rat thoracic aorta was taken and the surrounding connective tissue was removed. The blood vessels were cut into 3-4 mm blood vessel rings and suspended horizontally in a tracheal bath tube filled with KH solution. A tension transducer was connected and a 95% O2+5% CO2 mixed gas was continuously supplied to the bath tube. After the rat blood vessel rings were stable, 1 μmol / L phenylephrine was administered to ensure the stability of the blood vessels. After the tension was restored to 1.0 g, the blood vessels were contracted again with 1 μmol / L phenylephrine. After reaching the peak value for 10 minutes, 10 μmol / L phenylephrine was administered cumulatively. -9 ~10 -5 After the cumulative reaction stabilizes, it will balance to the basic tension. After the vasoconstriction reaches the peak, the cumulative administration of 10 -8 ~10 -4 The maximum contraction amplitude induced by 1 μmol / L phenylephrine was 100%, and the ratio between the vascular relaxation amplitude after adding acetylcholine or acidified sodium nitrite and the maximum contraction amplitude induced by phenylephrine was recorded as the change value of vascular tension.

[0103] 4. Statistical Analysis

[0104] SPSS 22.0 statistical software was used to analyze the data. The comparison among multiple groups was performed by one-way analysis of variance, and the comparison between two groups was performed by LSD test. P<0.05 was considered statistically significant.

[0105] 5. Results

[0106] 1) Effects on rat body weight

[0107] After administration, the body weight of rats in the normal group increased by 20.8±2.9 g. Compared with the normal group, the body weight gain of rats in the model group was significantly increased (32.6±4.3 g, P<0.05). The body weight gain of the ligustrazine group was 29.4±2.7 g, the compound 1 group was 22.3±1.8 g, and the compound 4 group was 24.3±2.0 g.

[0108] 2) Effects on TNF-α, IL-6 and IL-1β in rats

[0109] As shown in Table 1, compared with the normal group, the levels of TNF-α, IL-6 and IL-1β in the plasma of the rats in the model group were significantly increased (P<0.05); compared with the model group, the levels of TNF-α, IL-6 and IL-1β in the plasma of the rats in the drug administration group were significantly decreased (P<0.05), and the effect of the compound of the present invention on reducing the levels of TNF-α, IL-6 and IL-1β was significantly better than that of ligustrazine (P<0.05).

[0110] Table 1: Comparison of plasma TNF-α, IL-6 and IL-1β levels in rats of each group

[0111]

[0112] Note: Compared with the normal group, * P<0.05; compared with the model group, # P<0.05; compared with the ligustrazine group, & P<0.05

[0113] 3) Effects on blood lipid levels in rats

[0114] As shown in Table 2, compared with the normal group, the serum total cholesterol, triglyceride, LDL-C levels and AI of the rats in the model group were significantly increased, and the HDL-C level was significantly decreased (P<0.05); compared with the model group, the serum total cholesterol, triglyceride, LDL-C levels and AI of the rats in the drug administration group were significantly decreased (P<0.05), and the effect of the compound of the present invention was significantly better than that of ligustrazine (P<0.05).

[0115] Table 2: Comparison of serum total cholesterol, triglyceride, LDL-C levels and AI levels in rats of each group

[0116]

[0117] Note: Compared with the normal group, * P<0.05; compared with the model group, # P<0.05; compared with the ligustrazine group, & P<0.05

[0118] 4) Effects on endothelial function of rat thoracic aorta

[0119] As shown in Table 3, after stimulating the thoracic aorta of rats with acetylcholine, the change value of vascular tension of rats in the model group was significantly increased compared with the normal group (P<0.05); compared with the model group, the change value of vascular tension of rats in the drug administration group was significantly reduced (P<0.05), and the effect of the compound of the present invention was significantly better than that of ligustrazine (P<0.05). There was no statistically significant difference in the change value of vascular tension of the thoracic aorta of rats in each group after treatment with acidified sodium nitrite.

[0120] Table 3: Comparison of changes in thoracic aorta vascular tension in rats of each group

[0121]

[0122] Note: Compared with the normal group, * P<0.05; compared with the model group, # P<0.05; compared with the ligustrazine group, & P<0.05

[0123] In general, the compounds of the present invention have significant effects on controlling the weight gain of rats, reducing the levels of TNF-α, IL-6 and IL-1β in plasma, the levels of serum total cholesterol, triglycerides, LDL-C and AI, and changes in vascular tension, as well as increasing the level of serum HDL-C, indicating that the compounds of the present invention can improve the body weight, abnormal inflammatory factors and blood lipid levels in rats with coronary heart disease, thereby reducing vascular endothelial damage, protecting vascular endothelial function in rats with coronary heart disease, and alleviating disease progression.

[0124] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A compound of formula I or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof: in, R1-R3 are the same or different, and are independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl, and R1-R3 are not all hydrogen; L is selected from C1-C6 alkylene; R4 and R5 are the same or different and are independently selected from hydrogen, C1-C6 alkyl, and halogenated C1-C6 alkyl; X is selected from O or S.

2. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof, characterized in that: R1-R3 are the same or different and are independently selected from hydrogen, methyl, ethyl, hydroxymethyl and trifluoromethyl.

3. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof, characterized in that: R1-R3 are all selected from methyl; or, R1 and R2 are selected from hydrogen, and R3 is selected from methyl or trifluoromethyl.

4. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof, characterized in that: L is selected from -(CH2) m -, m is 1, 2, 3, 4, 5 or 6; preferably, L is selected from -CH2-, -CH2CH2-.

5. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof, characterized in that: R4 and R5 are the same or different and are independently selected from hydrogen, methyl and ethyl.

6. The compound of formula I according to claim 1 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, or tautomer thereof, characterized in that: The compound is selected from:

7. A method for preparing the compound of formula I in claim 1, the method comprising: wherein Xa represents a halogen; Step 1: reacting a compound of formula a with hydrazine hydrate to produce an intermediate of formula b; Step 2: React the intermediate of formula b with an aldehyde of formula c to produce a compound of formula I.

8. Use of a compound of formula I according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or tautomer thereof in the preparation of a drug for treating cardiovascular diseases.

9. Use of a compound of formula I according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or tautomer thereof in the preparation of a cardiovascular protective drug.

10. A pharmaceutical composition comprising a compound of formula I according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, solvate, hydrate, prodrug or tautomer thereof.

Citation Information

Patent Citations

  • Diazepane derivatives and uses thereof

    CN106715437A

  • Application of ligustrazine nitrone derivative in prevention and treatment of diabetic complication diseases

    CN107157999A

  • Ligustrazine derivative and preparation method thereof

    CN112961143A

  • NO donor type ligustrazine derivative, preparation method, composition and application

    CN116063237A

  • Preparation method of honokiol-ligustrazine eutectic crystal

    CN116969898A